AlphAIAlphAI — Financial news for AI agents
investing.comSEP 91 min read$SMMT

Summit Therapeutics stock surges on Jefferies upgrade to buy

Summit Therapeutics (SMMT) shares rose 5.8% premarket after Jefferies upgraded it to Buy and raised its price target to $25. The upgrade is ahead of expected H3 progression-free survival data in late 2026, with Jefferies predicting statistical significance and a potential overall survival win by early 2027. The analyst cited the company's mechanism of action and ivonescimab's first-in-class status as key drivers.

Original reporting
investing.com
Published Sep 9, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 1:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$SMMT
Bullish
high confidence
Mentioned
$SMMT
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SMMTBullishHigh
01

Why it matters

The upgrade could attract short‑term buying pressure and lift the stock toward the new $25 target.

02

Market read

A notable pre‑market move driven by analyst sentiment, relevant for traders targeting biotech momentum.

03

What to watch

Potential regulatory delays in China could affect global trial timelines.

Relevance 7/10Novelty 7/10Timing: premarket today

Background

Summit Therapeutics is developing ivonescimab for oncology indications; the upgrade precedes H3 trial data.

Company-level read

Ticker impact

$SMMTBullishHigh confidence
Context

Jefferies upgraded Summit Therapeutics to Buy and raised the price target to $25, prompting a 5.8% pre‑market price jump.

Expected impact

Potential further intraday rally, with upside to $25 target.

Evidence & confidence

Analyst cites strong progression‑free survival expectations and first‑in‑class mechanism, supporting higher valuation.

Market effects

Sector

Biotech sector may see renewed interest in oncology trials following the upgrade.

Regional

Limited to U.S. biotech equities; no broad regional effect.

Global

Minor, as the news is company‑specific.

Counterpoint

What could challenge this read

Upgrade may be premature if upcoming trial data disappoint, risking a pull‑back.

Key entities

  • analyst
    Jefferies

    Provided the upgrade and price target increase.

  • company
    Summit Therapeutics

    Biopharma firm receiving the upgrade.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 9
$SMMTHighAI 9/10

Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab

Summit Therapeutics (SMMT) announced that its partner Akeso reported a statistically significant overall survival benefit for ivonescimab over pembrolizumab in the Phase 3 HARMONi-2 study. The trial involved 398 patients with advanced non-small cell lung cancer. Earlier data showed ivonescimab's median progression-free survival was 11.1 months, compared to 5.8 months for pembrolizumab. The hazard ratio was 0.51, indicating a 49% reduction in progression or death risk. Summit did not disclose the

yahoo.com2 min
SEP 7
$SMMTMedAI 8/10

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress

Summit Therapeutics (SMMT) shares rose 28.19% week-on-week after its partner, Akeso, reported positive Phase 3 trial results for ivonescimab in non-small cell lung cancer, showing improved overall survival over pembrolizumab. Additionally, ivonescimab demonstrated superiority in a biliary tract cancer trial. Final results are pending presentation at medical conferences. Institutional investors reduced holdings despite increased hedge fund interest.

yahoo.com2 min
SEP 4
$SMMTHighAI 9/10

Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival Data - And What's Next

Summit Therapeutics (SMMT) shares rose 19.5% after its partner, Akeso Inc., reported positive Phase III trial results for ivonescimab in biliary tract cancer. The drug showed significant survival and response benefits over a competitor. Summit projects $897.3M revenue and $169.7M earnings by 2029, implying a 66% upside. The FDA decision on ivonescimab's BLA is a key upcoming catalyst.

simplywall.st2 min